1Ruijter E,Van De Kaa C,Miller G,et al.Molecular genetics and epidemiology of prostate carcinoma [J].Endocr Rev,1999,20:22-45.
2Miller G.Vitamin D and prostate cancer:biologic interactions a nd clinical potentials [J].Cancer Met Rev,1999,17:353-360.
3Blutt S,Weigel N.Vitamin D and prostate cancer [J].Proc Soc Exp Biol Med,1999,211:89-98.
4Taylor J A,Hirvone A,Watson M,et al.Association of prostate ca ncer with vitamin D receptor gene polymorphism [J].Cancer Res,1996,56:4108-41 10.
5Ingles S A,Ress R K,Yu M C,et al.Association of prostate cance r risk with genetic polymorphisms in vitamin D receptor and androgen receptor [ J].J Natl Cancer Inst,1997,89:166-170.
6Hedlund T,Moffatt K,Miller G.Vitamin D receptor expression is required for growth modulation by 1,25-dihydroxyvitamin D3 in the human prost ate carcinoma cell line ALVA31 [J].J Steroid Biochem Mol Biol,1996,58:277-288 .
7Miller G J,Stapleton G E,Hedlund T E,et al.Vitamin D receptor expression 24-hydroxylase activity and inhibition of growth by 1α,25-dihydrox yvitamin D3 in seven human prostate carcinoma cell line [J].Clin Cancer Res, 1995,1:997-1003.
8Ly L H,Zhao X Y,Hollway L,et al.Liarozole acts synergistically with 1α,25-dihydroxyvitamin D3 to inhibit growth of DU145 human prostate ca ncer cells by blocking 24-hydroxylase activity [J].Endocrinology,1999,140:207 1-2076.
9Liu M,Lee M,Cohen M,et al.Transcriptional activation of the CD K inhibitor p21 by vitamin D leads to the induced differentiation of the myelomo nocytic cell line U-937 [J].Gen Develop,1996,10:142-153.
10Zhuang S H,Bumstein K L.Antiproliferative effect of 1α,25-dihydroxyvit amin D3 in human prostate cancer cell line LNCaP involves reduction of cyclin -dependent kinase 2 activity and persistents G1 accumulation [J].Endocrinolog y,1998,139:1197-1207.
